By Fineline Cube 
Novartis AG (NYSE: NVS) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending marketing authorization for Itvisma™ (intrathecal onasemnogene abeparvovec) to treat children, adolescents, and adults aged 2 years and older with 5q spinal muscular atrophy (SMA) due to biallelic SMN1 gene mutations.
Itvisma is a one-time, intrathecally administered gene therapy based on an adeno-associated virus serotype 9 (AAV9) vector engineered to deliver a functional copy of the human SMN1 gene directly to the central nervous system. By enabling sustained expression of survival motor neuron (SMN) protein, the therapy addresses SMA at its genetic root cause, with clinical data showing meaningful improvements in motor function across age groups.
Regulatory & Product Profile
| Parameter | Detail |
|---|---|
| Drug Name | Itvisma™ (onasemnogene abeparvovec, intrathecal formulation) |
| Indication | 5q SMA with biallelic SMN1 mutations, age ≥2 years |
| Mechanism | AAV9-mediated delivery of functional SMN1 gene via single intrathecal injection |
| EMA Status | CHMP positive opinion → marketing authorization decision expected Q3 2026 from European Commission |
| U.S. Status | Already approved and marketed as Itvisma (same product, formerly OAV101B) |
| Differentiation | First intrathecal (vs. intravenous) AAV9-SMN1 gene therapy approved globally; designed for older/larger patients where IV dosing faces vector load limitations |
Clinical & Strategic Significance
- Broad Eligibility: Unlike earlier gene therapies restricted to infants <2 years, Itvisma extends potential benefit to older children, teens, and adults—a population historically excluded from curative approaches
- Dosing Advantage: Intrathecal route reduces systemic vector exposure, potentially lowering liver toxicity risks associated with high-dose IV AAV9
- Franchise Expansion: Complements Novartis’ existing SMA portfolio, including oral Evrysdi® (risdiplam), offering a one-time treatment option for eligible patients
- Market Access: Expected premium pricing (~€2–3 million per dose), justified by lifetime cost-of-care avoidance in progressive neuromuscular disease
Competitive & Therapeutic Context
SMA affects ~1 in 10,000 births and is the leading genetic cause of infant mortality. While Zolgensma® (IV onasemnogene abeparvovec) revolutionized infant care, Itvisma fills a critical gap for non-ambulatory or older patients who cannot receive IV gene therapy due to weight-based vector caps. The CHMP endorsement validates this differentiated delivery strategy.
Forward‑Looking Statements
This brief reflects a regulatory milestone. Final EU approval, reimbursement negotiations, and real-world adoption remain subject to European Commission decision and national health technology assessments.-Fineline Info & Tech